Genmab A/S (OTCMKTS:GNMSF) Releases Quarterly Earnings Results, Beats Estimates By $2.15 EPS

Genmab A/S (OTCMKTS:GNMSF) posted its quarterly earnings results on Thursday. The company reported $5.64 EPS for the quarter, beating the consensus estimate of $3.49 by $2.15, Zacks reports. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The business had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.20 billion.

Genmab A/S Stock Down 2.2%

OTCMKTS GNMSF traded down $12.00 on Friday, reaching $526.00. The stock had a trading volume of 7 shares, compared to its average volume of 7,725. The business has a 50 day moving average price of $391.48 and a 200 day moving average price of $310.32. The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81. Genmab A/S has a 1 year low of $232.34 and a 1 year high of $581.00. The company has a market capitalization of $32.39 billion, a price-to-earnings ratio of 44.58 and a beta of 0.64.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary technologies to create differentiated antibodies and antibody-drug conjugates designed to engage the immune system or target specific disease-related proteins.

Genmab’s technologies include the DuoBody platform for generating bispecific antibodies, as well as the HexaBody platform for developing antibodies with enhanced activity.